Cas:21082-33-7 Orcinol glucoside manufacturer & supplier

Chemical Name:Orcinol glucoside

CAS.NO:21082-33-7

Synonyms:Orcinol glucoside;3-Hydroxy-5-methylphenyl D-glucopyranoside;D-Glucopyranoside, 3-hydroxy-5-methylphenyl

Molecular Formula:C₁₃H₁₈O₇

Molecular Weight:286.278

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:570.6±50.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.637

PSA:119.61000

Exact Mass:286.105255

LogP:-0.77

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Orcinol glucoside chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,D-Glucopyranoside, 3-hydroxy-5-methylphenyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D-Glucopyranoside, 3-hydroxy-5-methylphenyl Use and application,Orcinol glucoside technical grade,usp/ep/jp grade.

Related News: Flexibility in a CDMO is the key to ensure speed of tech-transfer which is a true litmus test for CDMOs which can help a company chose between competing analytical strategies, manufacturing technology and knowledge for improving productivity. 4-(4-acetoxy-3-methoxy-phenyl)-1,3,4,5-tetrahydro-benzo[b][1,4]diazepin-2-one semicarbazone manufacturers Earlier this month, the drugmaker lifted a voluntary EU marketing hold on Zynteglo for beta thalassemia, after a patient death in one of the drugmaker’s other products, LentiGlobin, halted clinical studies. N-(4,6-dimethoxy-1,3,5-triazin-2-yl)-N’-(2-methoxy-6-methyl-phenylsulphonyl)-urea suppliers Earlier this month, the drugmaker lifted a voluntary EU marketing hold on Zynteglo for beta thalassemia, after a patient death in one of the drugmaker’s other products, LentiGlobin, halted clinical studies. Acetoxy-benzolsulfonyl-(p-methoxy-benzoyl)-methan vendor & factory Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. ,Flexibility in a CDMO is the key to ensure speed of tech-transfer which is a true litmus test for CDMOs which can help a company chose between competing analytical strategies, manufacturing technology and knowledge for improving productivity.